Business Context and Reporting Period
This Form 8-K is a current report filed by Signal Genetics, Inc. on January 29, 2015. The filing provides preliminary estimates for the year ended December 31, 2014. The company is currently finalizing its financial results and has not yet completed normal closing or audit procedures.
Key Financial Metrics
- Net Revenue (Preliminary): Estimated between $4.1 million and $4.5 million for the year ended December 31, 2014.
- Revenue Adjustments: Includes unfavorable changes in estimates of $0.4 million recorded as adjustments to prior year revenues.
- Customer Breakdown:
- University of Arkansas for Medical Sciences (UAMS): 3,671 tests generating approximately $3.6 million (net of $0.2 million prior year adjustment).
- Non-UAMS Hospital Customers: 509 tests (a 50% increase over the prior year) generating approximately $0.7 million (net of $0.2 million prior year adjustment).
- Cash Position: Estimated at approximately $5.1 million as of December 31, 2014.
- Outstanding Shares: 3,808,563 shares of common stock outstanding as of the filing date.
- Profit, Margins, and Debt: The filing text does not provide clear values for net income, profit margins, or debt levels.
Material Changes
Non-UAMS hospital test volume increased by 50% compared to the prior year. The company recorded $0.4 million in unfavorable revenue adjustments related to prior year estimates, which reduced the reported net revenue for the current period.
Outlook, Risks, and Management Commentary
Management emphasizes that these figures are preliminary estimates. There is no assurance that final results will not differ materially due to year-end closing procedures or audit adjustments. The filing explicitly states these estimates should not be viewed as a substitute for full audited financial statements prepared in accordance with GAAP.
Investor Verification Checklist
- Verify the final audited revenue figures once the 10-K is filed to confirm the $4.1 million to $4.5 million range.
- Confirm the final cash balance and any changes resulting from audit adjustments.
- Review the detailed nature of the $0.4 million unfavorable revenue adjustments to understand the impact on prior year comparability.
- Monitor the company's liquidity runway given the preliminary cash position of $5.1 million.